Agenus (NASDAQ:AGEN) Stock Rating Upgraded by Wall Street Zen
by Tristan Rich · The Markets DailyAgenus (NASDAQ:AGEN – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.
Several other analysts have also commented on AGEN. B. Riley Financial reissued a “buy” rating and issued a $14.00 price objective (up from $8.00) on shares of Agenus in a report on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. HC Wainwright increased their target price on Agenus from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, Zacks Research cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Agenus has an average rating of “Hold” and an average price target of $22.00.
Get Our Latest Research Report on Agenus
Agenus Price Performance
AGEN stock opened at $7.50 on Friday. Agenus has a 52-week low of $2.71 and a 52-week high of $8.70. The firm has a market cap of $335.62 million, a P/E ratio of 4.72 and a beta of 1.40. The company’s 50-day simple moving average is $4.04 and its 200-day simple moving average is $3.69.
Agenus (NASDAQ:AGEN – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing the consensus estimate of $2.10 by ($1.08). The business had revenue of $33.74 million during the quarter, compared to analysts’ expectations of $129.50 million. Agenus had a net margin of 50.49% and a negative return on equity of 31.66%. On average, analysts anticipate that Agenus will post -0.2 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Agenus
Several large investors have recently bought and sold shares of AGEN. EP Wealth Advisors LLC acquired a new position in shares of Agenus during the fourth quarter valued at approximately $31,000. R Squared Ltd acquired a new stake in shares of Agenus in the fourth quarter worth approximately $41,000. Redwood Family Wealth LLC acquired a new stake in shares of Agenus in the fourth quarter worth approximately $44,000. Quadrature Capital Ltd purchased a new stake in shares of Agenus during the fourth quarter worth approximately $54,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Agenus during the third quarter worth approximately $54,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.
Agenus Company Profile
Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.
Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.